Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Phase III trials are conducted to provide stronger evidence of the effectiveness and safety of a therapeutic intervention and typically form a key part of applications to regulatory authorities to grant market approval. They usually involve 500-3000 or more patients and compare the therapeutic intervention with the current standard of care for patients with the disease intended to be treated.
The phase 3 CAPRI clinical trial evaluating the impact of a digital nurse navigator-led system in patients receiving oral anticancer treatment shows that remote monitoring using a smartphone app results in an improved patient care experience and optimizes healthcare resources.
AstraZeneca has introduced digital health solutions into clinical trials, demonstrating improved patient experience, accelerated timelines and reduced costs.
In a phase III trial, the oral Janus kinase inhibitor baricitinib was safe and effective in patients with juvenile idiopathic arthritis who previously had an inadequate response to DMARD therapy.
The IL-17A–IL-17F inhibitor bimekizumab is safe and effective for the treatment of both radiographic and non-radiographic axial spondyloarthritis, according to the results of two parallel phase III trials.
